GSK plc
↗London, United Kingdom
GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, England, specializing in medicines, vaccines, and specialty pharmaceuticals. Formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK transformed itself in 2022 to rebrand as 'GSK plc' and spun off its Consumer Healthcare business into a separate company (now Haleon). The company is now a dedicated biopharma company focused on four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. GSK maintains a global R&D network with major hubs in the United States, United Kingdom, Belgium, Italy, Spain, and Poland, operating 37 medicines and vaccines manufacturing sites worldwide. The company generated £31.37 billion in revenue in 2024 and projects sales exceeding £40 billion by 2031, with specialty medicines representing close to 40% of current sales and expected to exceed 50% by 2031.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals, Vaccines, Biotechnology
SIZE & FINANCIALS
Employees:10000+
Revenue:$30B-$40B
Founded:1715
Ownership:public
Status:operating
STOCK
Exchange:LSE, NYSE
Ticker:GSK
Market Cap:$97.83B
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 3 and Registration
Modalities:Small molecule, mAb, ADC, Vaccines, Oligonucleotides, Long-acting injectables
Trial Phases:-
FDA Approvals:5
EMA Approvals:4
CORPORATE STRUCTURE
Subsidiaries:ViiV Healthcare (76.5% ownership; specializes in HIV medicines, joint venture with Pfizer 13.5% and Shionogi 10%)
Key Partnerships:ViiV Healthcare - HIV medicines joint venture with Pfizer and Shionogi, University of Dundee and University of Exeter - Fungal disease research partnership, Medicines Patent Pool - Voluntary licensing for HIV treatments, Global Fund - HIV, TB, and malaria health solutions, Empirico Inc. - Oligonucleotide respiratory disease candidate acquisition, Syndivia - ADC licensing agreement for prostate cancer, Samsung Biologics - Manufacturing partnership for US biologics production
COMPETITION
Position:Leader
Competitors:AstraZeneca, Pfizer, Novartis, Merck, Johnson & Johnson, Roche, Takeda, Bayer +6 more
LEADERSHIP
Key Executives:
Emma Walmsley - CEO (until December 31, 2025)
Luke Miels - CEO Designate (assumes role January 1, 2026)
Julie Brown - Chief Financial Officer
Phil Thomson - President of Global Affairs
Deborah Waterhouse - GSK Leadership Team Member
Board Members:Company Chair, 2 Executive Directors, 8 independent Non-Executive Directors
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with GSK plc. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.